Advances in microRNA analysis

Kalogianni, Despina P.; Kalligosfyri, Panagiota M.; Kyriakou, Iraklis K.; Christopoulos, Theodore K.

doi:10.1007/s00216-017-0632-z

Cited by 51 publications

(30 citation statements)

References 106 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…It has been estimated that up to 50% of human protein-coding genes are regulated by miRNAs (4). Each miRNA has the potential to regulate hundreds of RNAs, and their expression is associated with tissue status and disease subtype (5). miRNAs have been demonstrated to serve an important role in the development and prognosis of glioma.…”

Section: Introductionmentioning

confidence: 99%

MicroRNA‑6852 suppresses glioma A172 cell proliferation and invasion by targeting LEF1

et al. 2019

View full text Add to dashboard Cite

microRNA (miR)-6852 has been demonstrated to suppress the progression of gastric, colorectal and cervical cancer. The mechanism by which miR-6852 regulates glioma cells is yet to be elucidated. In the present study, reverse transcription-quantitative PCR analysis was used and the results demonstrated that miR-6852 expression was reduced in glioma tissues and cells. Cell counting kit-8 and transwell assay analysis indicated that proliferation, migration and invasion of A172 cells in the miR-6852 mimic group were lower than in the miR-NC group. Compared with the Inh-NC group, A172 cells of the Inh-miR-6852 group exhibited higher proliferation, migration and invasion. Additionally, the results indicated that lymphoid enhancer binding factor 1 (LEF1) was directly inhibited by miR-6852 and LEF1 expression was negatively correlated with miR-6852 expression in glioma tissues. Furthermore, the restoration of LEF1 reversed the effects of the miR-6852 mimics. The present findings suggested that miR-6852 inhibited glioma cells proliferation, migration and invasion by targeting the suppression of LEF1. Recently, miR-6852 has been demonstrated to be associated with the development of tumors, including those in gastric, colorectal and cervical cancer (9-11). The association of miR-6852 with glioma remains undetermined. Therefore, the present study aimed to assess miR-6852 expression in glioma, and further determine the effect of miR-6852 in the regulation of glioma progression. Materials and methodsGlioma tissue collection. A total of 32 pairs of glioma tissues (14 males and 18 females; age range, 31-56 years old; median age, 47 years old) and corresponding normal tissues were collected during biopsy from Affiliated Hospital of Hebei University (Hebei, China) between October 2014 and October 2016 for the current study. Normal tissues were derived from the temporal lobes and saddle area 2 cm away from tumor tissues. All glioma tissues were obtained from patients upon first diagnosis of glioma. Among these patients, 18 cases were high-grade and 14 cases were low-grade. All patients did not recieve radiotherapy or chemotherapy prior to surgery. Patients

show abstract

Section: Introductionmentioning

confidence: 99%

MicroRNA‑6852 suppresses glioma A172 cell proliferation and invasion by targeting LEF1

et al. 2019

View full text Add to dashboard Cite

show abstract

“…One reasonable explanation for this finding might be that these platforms were developed to detect and quantify gene expression patterns, but might fail when dealing with miRNAs. These specific difficulties might be due to (i) the short nucleotide sequence of miRNAs thereby limiting the options for primer design, (ii) the need to differentiate between mature miRNAs from their precursors, as well as (iii) the multiplicity and dynamic range of miRNAs [ 75 ]. Recently, RNA sequencing as the most sensitive method has been successfully implemented for the identification of miRNAs.…”

Section: Methodical Strategies and Specific Challenges Regarding Mmentioning

confidence: 99%

Expression, Regulation and Function of microRNA as Important Players in the Transition of MDS to Secondary AML and Their Cross Talk to RNA-Binding Proteins

Bauer

Vaxevanis

Heimer

et al. 2020

IJMS

View full text Add to dashboard Cite

Myelodysplastic syndromes (MDS), heterogeneous diseases of hematopoietic stem cells, exhibit a significant risk of progression to secondary acute myeloid leukemia (sAML) that are typically accompanied by MDS-related changes and therefore significantly differ to de novo acute myeloid leukemia (AML). Within these disorders, the spectrum of cytogenetic alterations and oncogenic mutations, the extent of a predisposing defective osteohematopoietic niche, and the irregularity of the tumor microenvironment is highly diverse. However, the exact underlying pathophysiological mechanisms resulting in hematopoietic failure in patients with MDS and sAML remain elusive. There is recent evidence that the post-transcriptional control of gene expression mediated by microRNAs (miRNAs), long noncoding RNAs, and/or RNA-binding proteins (RBPs) are key components in the pathogenic events of both diseases. In addition, an interplay between RBPs and miRNAs has been postulated in MDS and sAML. Although a plethora of miRNAs is aberrantly expressed in MDS and sAML, their expression pattern significantly depends on the cell type and on the molecular make-up of the sample, including chromosomal alterations and single nucleotide polymorphisms, which also reflects their role in disease progression and prediction. Decreased expression levels of miRNAs or RBPs preventing the maturation or inhibiting translation of genes involved in pathogenesis of both diseases were found. Therefore, this review will summarize the current knowledge regarding the heterogeneity of expression, function, and clinical relevance of miRNAs, its link to molecular abnormalities in MDS and sAML with specific focus on the interplay with RBPs, and the current treatment options. This information might improve the use of miRNAs and/or RBPs as prognostic markers and therapeutic targets for both malignancies.

show abstract

“…More important, upon recognition of targets, NA probes form characteristic higher‐order conformational changes through hydrogen bonding, electrostatic interactions, shape effect, aromatic ring and/or base pairs aggradation, which allow them to open up a vast repertoire of target recognition and signal transduction patterns. For instance, NA probes have recently been incorporated into paper‐based analytical platforms for detecting nearly all chemical and biological entities, such as metal ions (J. Chen, Zhou, & Wen, ), NAs (Restaino & White, ), microRNA (Kalogianni, Kalligosfyri, Kyriakou, & Christopoulos, ), amino acids (Kaspar, Dettmer, Gronwald, & Oefner, ), polypeptide (Cao et al, ), protein complex (Saha & Jana, ), polysaccharides (S. Wang et al, ), carbohydrate (Yang et al, ), small organic compounds (Conzuelo et al, ), virus particles (Teengam, Siangproh, Tuantranont, Henry et al, ), bacteria (Burlage & Tillmann, ), and organelles and surface markers of cells (Shah, Kaushik, Zhu, Zhang, & Li, ).…”

Section: Introductionmentioning

confidence: 99%

Paper‐based point‐of‐care test with xeno nucleic acid probes

Xiao

Jin

et al. 2019

Biotech & Bioengineering

View full text Add to dashboard Cite

Bridging the unmet need of efficient point-of-care testing (POCT) in biomedical engineering research and practice with the emerging development in artificial synthetic xeno nucleic acids (XNAs), this review summarized the recent development in paperbased POCT using XNAs as sensing probes. Alongside the signal transducing mode and immobilization methods of XNA probes, a detailed evaluation of probe performance was disclosed. With these new aspects, both researchers in synthetic chemistry / biomedical engineering and physicians in clinical practice could gain new insights in designing, manufacturing and choosing suitable reagents and techniques for POCT. K E Y W O R D S aptamer, chemical modification, paper-based analytical devices (PADs), point-of-care testing (POCT), xeno nucleic acids (XNAs)

show abstract

Advances in microRNA analysis

Cited by 51 publications

References 106 publications

MicroRNA‑6852 suppresses glioma A172 cell proliferation and invasion by targeting LEF1

MicroRNA‑6852 suppresses glioma A172 cell proliferation and invasion by targeting LEF1

Expression, Regulation and Function of microRNA as Important Players in the Transition of MDS to Secondary AML and Their Cross Talk to RNA-Binding Proteins

Paper‐based point‐of‐care test with xeno nucleic acid probes

Contact Info

Product

Resources

About